In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Gilead Sciences trades 20% above a high-confidence fair value of $134.40, indicating potential overvaluation despite excellent profitability and efficiency scores. Monte Carlo analysis shows high volatility and downside risk, with a median value below the current price. Valuation methods converge on mid-to-high $100s, reflecting mixed signals on growth and leverage concerns.